The following is a summary of the Viatris Inc. (VTRS) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Viatris reported Q2 revenue of $3.8 billion with operational revenue growth of approximately 2%.

• Adjusted EBITDA for Q2 was $1.2 billion, also growing about 2% from the previous year.

• Adjusted EPS was reported at $0.69 per share.

• Free cash flow for Q2 was significant at $426 million, excluding transaction costs and taxes.

Business Progress:

• Viatris has completed strategic divestitures, enhancing focus on core business and innovative assets.

• The company has integrated two global companies, streamlined operations, and returned to base business growth.

• Viatris emphasizes investments in a portfolio of innovative, patent-protected assets in areas like cardiovascular disease and immunology.

Opportunities:

• Plans to expand and accelerate growth in innovative portfolio, particularly in cardiovascular and immunology treatments.

• Leveraging robust cash flows and strong balance sheet for strategic investments and innovation.

Risks:

• Managing ongoing shifts due to therapy changes in the ARV market and impacts from government price regulations in Japan and Australia.

More details: Viatris IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.